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To evaluate the impact of BRCA1/2 testing
and disclosure of a positive test result on
women affected and unaffected with cancer.
Longitudinal cohort study including women
affected and unaffected with breast or ovar-
ian cancer testing for a BRCA1/2 mutation.
Data on well-being (anxiety, depression,
cancer related distress, general health),
treatment choice, and decision making
about cancer prevention were collected at
baseline (1 week after blood sampling; affec-
ted n¼192, unaffected n¼176) and at follow-
up (2 weeks after disclosure of a positive test
result; affected n¼23, unaffected n¼66).
Women affected and unaffected with breast
or ovarian cancer were compared using
univariate statistics. Change over time was
examined using repeated measures analysis
of variance. With respect to well-being,
affected women scored worse at baseline.
At follow-up, both affected and unaffected
women experienced a decline in well-being,
which tended to be stronger in affected
women. Women diagnosed with cancer less
than 1 year previously tended to report a
worse well-being than those diagnosed
longer ago. With respect to treatment choice,
more affected women intended to obtain
prophylactic surgery and valued it higher
at both time points. With respect to decision
making, affected women had a lower pre-
ference for participation in decision making
at baseline; no differences were found at
follow-up. At follow-up, both affected and
unaffected women showed an increase in
strength of treatment preference and a
decrease in decision uncertainty. Disclosure
of a positive test result had a negative impact
on well-being. Affected women, especially
thosewhohavebeenrecentlydiagnosedwith
cancer,experiencedtheworstwell-beingand
could benefit from psychosocial support.
 2003 Wiley-Liss, Inc.




The identification of the BRCA1 and BRCA2 genes
has created the possibility to test for inherited suscept-
ibility of breast and ovarian cancer [Miki et al., 1994;
Wooster et al., 1995]. Diagnostic genetic testing in a
family usually begins in a woman affected with cancer
(index case). Once a mutation is detected, predictive
testing can be performed in other family members.
Affected mutation carriers have a high risk of develop-
ing a second cancer [Ford et al., 1998]. Unaffected
mutation carriers have a high cumulative lifetime risk
for breast (56 to 85%) and ovarian cancer (16 to 63%)
[Easton et al., 1995; Struewing et al., 1997; Whittemore
et al., 1997; Ford et al., 1998]. In the Netherlands,
mutation carriers currently face the difficult choice
between prophylactic surgery and screening of breasts
and/or ovaries.
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Because genetic testing and disclosure of a positive
test result may have far reaching consequences for both
affected and unaffected women, it is important to
monitor the impact on well-being and decision making
about cancer prevention. A priori, one might assume
that genetic testing and disclosure of a positive test
result may cause distress. However, previous studies
evaluating the impact of genetic testing and disclosure
of a positive test result, showed low levels of general and
cancer relateddistress [Lermanetal., 1996;Croyle etal.,
1997; Lodder et al., 1999, 2001; Coyne et al., 2000;Wood
et al., 2000; Schwartz et al., 2002]. Some of these studies
evaluated changes in pre- and post-test distress and
found that mutation carriers showed no significant
increase in distress after learning their carrier status
[Lerman et al., 1996; Croyle et al., 1997; Wood et al.,
2000; Lodder et al., 2001; Schwartz et al., 2002].
Until now, no study specifically concentrated on the
differential impact of genetic testing on women affected
with cancer versus those unaffected. One study, includ-
ing women anticipating and receiving genetic testing,
reported that affected and unaffected women had
similar levels of distress [Coyne et al., 2000]. Another
study evaluated the impact of a positive test result and
found that mutation carriers with a history of cancer or
cancer-related surgery were less distressed than those
without such a history [Croyle et al., 1997]. A recent
study, including both affected index cases and their
unaffected relatives, looked at the impact of the test
resultwithin those groups andnot between those groups
[Schwartz et al., 2002].
The purpose of the present study was to evaluate the
impact of BRCA1/2 testing and disclosure of a positive
test result onwomenaffectedandunaffectedwithbreast
or ovarian cancer. We looked at a broad spectrum of
outcomes considering well-being and decision making.
Because little is known about the impact of genetic
testing and disclosure of a positive test result on affected
versus unaffected women, knowledge of the levels of
distress and theneed for help to cope andmakedecisions
may help to improve educational and counseling
programs.
This report is subsumed within a larger randomized
controlled trail on shared decision making. It was not
the primarily objective of that study to focus on the
differences between women affected and unaffected
with cancer. However, because we hypothesized that
affected women are different from unaffected women
with respect to well-being and decision making, we
conducted an interim analysis to compare affected and
unaffected women. When resources for supportive
services are scarce, it is important to distinguish those
who might benefit the most from additional support.
METHODS
Study Population
Womenaffected andunaffectedwithbreast or ovarian
cancer, who provided a blood sample for BRCA1/2
testing at the Family Cancer Clinics of the University
Hospitals of Nijmegen (accrual started March 1999),
Groningen (accrual started June 1999), and Maastricht
(accrual started January 2000), were eligible for
participation. The Eastern part of the Netherlands is
covered by these three clinics. Study entry closed in
November 2001. Women were excluded from the study
if they were unable to give informed consent, had
insufficient proficiency of the Dutch language, had
distant metastases, had undergone bilateral mastect-
omy and oophorectomy. Women recently treated for
cancer (less than 1 months ago) were also excluded
because we assumed that these women were still
recovering and were more engaged with the outcomes
of the curative treatment than with decision making
about cancer prevention.
Study Procedure
Datawere collected during a longitudinal randomized
trial on shared decision making including two decision
aids. This study was approved by the local research
ethics committees. This paper only reports the baseline
(1 week after blood sampling) and a follow-up assess-
ment (2 weeks after disclosure of a positive test result)
for affected and unaffected women. During this time
period, women had received the first decision aid either
before or after disclosure of a positive test result; this
decision aid consisted of a brochure and video providing
detailed information on prophylactic surgery and
screening and the consequences. This informative deci-
sion aid had positive effects on information related
outcomes only, and none, whatsoever, onwell-being and
decision making. Though, it did lead to more considera-
tions towards prophylactic surgery and higher valua-
tions for prophylactic surgery and lower valuations for
screening. Furthermore, because timing of the decision
aid had no effect, all women at follow-up were equal on
the outcome measures [Van Roosmalen et al., 2002b].
The second decision aid, consisting of value assessment
and individualized treatment information,will be evalu-
ated only in BRCA1/2 mutation carriers. The follow-up
timepoint reportedhere,will be thebaselineassessment
for this second intervention.
Clinical geneticists or genetic counselors briefly intro-
duced the study when a blood sample for genetic testing
was obtained. A research assistant subsequently con-
tacted thesewomenbyphone to confirmeligibility and to
discuss the study.Womenwho gave verbal consentwere
enrolled and were mailed an informative letter des-
cribing the study, a consent form, and the baseline
questionnaire. Two weeks after a positive test result,
women received a follow-up questionnaire by mail.
Standard Genetic Counseling
Before a blood sample for genetic testing is taken,
usually two counseling sessionswith a genetic counselor
or clinical geneticist take place including the following:
clarification of the patient’s increased risk status,
explanation of genetic cancer susceptibility, information
on the pros and cons of genetic testing, the possible
outcomes of testing, and limited data regarding cancer
screening and prophylactic surgery.When amutation is
found, more detailed information is provided on the
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possible treatment options and women are offered
additional consultations with specialist physicians
(medical oncologist, gynecologist, and surgeon). These
appointments usually take place a view weeks after
testing positive for aBRCA1/2mutation, this is after the
follow-up assessment reported here. A socialworker or a
psychologist is generally present when a positive test
result is disclosed to unaffected women.
MEASURES
Baseline Variables
Sociodemographics and medical history. Data
were obtained on sociodemographics (age, marital
status, education level, employment status, presence
of children, wanting (more) children, being religiously
affiliated) and medical history (personal and family
history of breast/ovarian cancer, time since last cancer
diagnosis, being an index case, having first degree
relativeswith breast/ovarian cancer, having first degree
relatives who died of breast/ovarian cancer).
Outcome Variables
Well-being
Anxiety. Anxiety was measured using the 20 items
of the State Anxiety scale of the Spielberger State-Trait
Anxiety Inventory (STAI) [Spielberger et al., 1983]. Sum
scores on this measure range from 20 to 80, with higher
scores representing higher levels of anxiety.
Depression. Depression was measured using the
20 items of the Center for Epidemiologic Studies
Depression Scale (CES-D) [Radloff, 1977]. Sum
scores on this measure range from 0 to 60, with higher
scores reflecting more depressive symptoms.
Cancer related distress. Cancer related distresswas
measured with the Impact of Event Scale (IES)
[Horowitz et al., 1979]. The two subscales ‘‘intrusion’’
(seven items) and ‘‘avoidance’’ (eight items) measure
becoming overwhelmed by thoughts and feelings about
cancer in the family and a tendency to avoid these
thoughts and feelings respectively. A four-point res-
ponse scale ranging from ‘‘not at all’’ to ‘‘often’’ was
employed and coded 0, 1, 3, and 5. Sum scores on this
measure range from 0 to 75, with higher scores
indicating more distress.
Adequate reliability rates for the above measures on
psychological well-being have been reported previously
in comparable samples [Lerman et al., 1996;Croyle et al.,
1997]. Consistent with past studies, the Cronbach’s
coefficients alpha inour sample for theSTAI-state,CESD
and IES were 0.95, 0.91, and 0.87, respectively.
General health. Women were asked to rate their
general health state during the last week on a 11-point
rating scale (0, very bad; 10, excellent).
Treatment choice. At baseline,womenwere asked
their intended treatment choice if found to be mutation
carrier. For the decision related to the breasts and
ovaries, the choice was between ‘‘prophylactic surgery,’’
‘‘screening,’’ and ‘‘undecided.’’ At follow-up, mutation
carriers were asked their intended treatment choice
using the same alternatives. To test differences in
treatmentchoice, treatmentchoicewasdichotomizedinto
prophylactic surgery versus another treatment choice
(i.e., ‘‘screening’’ and ‘‘undecided’’). Furthermore, women
were asked to value the treatment options ‘‘prophylactic
mastectomy,’’ ‘‘breast cancer screening,’’ ‘‘prophylactic
oophorectomy,’’ and ‘‘ovarian cancer screening’’ on a 10-
point rating scale (1, very bad; 10, excellent).
Decision making. The following three outcomes
were asked separately for the decision related to the
breasts and ovaries. An overall score was created by
adding the scores on the items for the decision related to
the breast and ovaries and by dividing this sum score by
the total number of items.
Strength of treatment preference. Strength of treat-
mentpreferencewasassessedona four-pointLikert scale
(1, weak preference; 4, very strong preference). Those
who had chosen ‘‘undecided’’ as treatment choice were
assigned a value of zero (no preference).
Decision uncertainty. Decision uncertainty was
measured using three items from the uncertainty
subscale of the Decisional Conflict Scale by O’Connor
[O’Connor, 1995] and adapted for this situation. Our
items were: ‘‘I doubt what to choose,’’ ‘‘This decision is
hard forme tomake,’’ and ‘‘I amnot surewhat to choose.’’
A five-point scale (1, very much disagree; 5, very
much agree) was used. The Cronbach’s coefficient alpha
was 0.89.
Preference for decision making. Preference for deci-
sion making was measured using the following two
decision making items from the Problem-Solving Deci-
sion-Making Scale (PSDM) from Deber et al. [1996].
The items were: ‘‘Given the risks and benefits of the
possible treatment options, who should decide how
acceptable those risks and benefits are for you,’’ and
‘‘Given the risks and benefits of the possible treatment
options, who should decide which treatment option
should be selected.’’ A five-point scale (1, doctor alone;
3, doctor and I equally; 5, I alone) was used. The
Cronbach’s coefficient alpha was 0.87.
Statistics. In multi-item scales with missing data,
we calculated scale values if at least half of the items
were filled out. We used the Statistical Package for the
Social Sciences (SPSS 10.0.5) to analyze the data.
Descriptive statistics were generated to describe the
total sample and the subsample of mutation carriers in
terms of sociodemographics andmedical history. Differ-
ences between affected and unaffected women on the
baseline variables and on the outcome variables (at
baseline and at follow-up) were explored using univari-
ate statistics (t-tests for independent samples and
w2-tests). Repeated measures analyses of variance were
performed to examine change over time (impact of a
positive test result) on well-being and decision making,
with cancer history (affected versus unaffected) as
between-groups factor. Levels of P 0.05 (two-tailed)
were regarded as statistically significant.
Because a previous study [Wood et al., 2000] found
thatwomen recently diagnosedwith cancer experienced
the greatest distress, additional analyses were done
within thegroupof affectedwomen.Differencesbetween
women diagnosed with cancer 1 year previously and
those diagnosed>1year inwell-being (at baselineandat
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follow-up) were explored using univariate statistics (t-
tests for independent samples). We also conducted
repeated measures analysis of variance to examine
change over time (impact of a positive test result) on
well-being,with time since diagnosis (1 year versus>1
year) as between-groups factor.
RESULTS
Participants
During the study period, 453 eligible women were
asked to participate in a longitudinal randomized trial
on shareddecisionmaking.The initial participation rate
was 86% (n¼390). Of the 390 women, 22 (6%) dropped
out between baseline and disclosure of the test result; 11
affected and 11 unaffected. Of these 22 women, 5
withdrew for emotional reasons related to the informa-
tive decision aid (4 affected and 1 unaffected). All
baseline analyses are on the remaining 368 women;
192 were affected and 176 were unaffected. Of the 192
affected women, 23 received a positive test result (20
BRCA1, 3 BRCA2). Of the 176 unaffected, 68 received a
positive test result (47 BRCA1, 21 BRCA2). Within the
subgroup of mutation carriers, all 23 affected women
were followed up, but 2 of the 68 unaffected women (3%;
1 BRCA1 and 1 BRCA2) withdrew because of high
distress caused by the test result.
Baseline Variables
Table I presents the sociodemographics and medical
history of the affected and unaffected women both
within the total sample and the subsample of mutation
carriers. Within the total sample, several differences
between affected and unaffected women were found: (1)
affected women were older (t¼7.62; P<0.001), (2) had
children more often (w2¼ 13.90; P< 0.001), (3) wanted
(more) children less often (w2¼37.99; P<0.001), (4)
were religiously affiliated more often (w2¼8.01;
P< 0.01), (5) had a family history of breast cancer only
more often (w2¼ 71.44;P< 0.001), (6) were an index case
more often (w2¼ 264.91; P<0.001), and (7) had first
degree relatives who had died of cancer less often
(w2¼8.59; P<0.01). Within the subsample of mutation
carriers, similar differences were found in 1, 3, 5, and 6,
but not in 2, 4, and 7.
Outcome Variables
Well-being. Table II presents the mean scores on
well-being and the results of the independent t-tests for
affected versus unaffected women in the total sample at
baseline. Affected women had higher scores on depres-
sion and cancer related distress, and a lower score on
general health.
The fifth column of Table III presents themean scores
on well-being for affected and unaffected women in the
subsample of mutation carriers at follow-up; the results
of the independent t-tests are not presented. No
differences were found for any of the well-being out-
comes, although affected women tended to score higher
on anxiety (t¼1.82, P¼0.07).
The last three columns of Table III present the results
of the repeated measures analysis of variance; no main
TABLE I. Baseline Variables for the Total Sample and the Subsample of Mutation Carriers Per Group (Affected and Unaffected)
Total Mutation carriers
Affected (n¼192) Unaffected (n¼ 176) Affected (n¼ 23) Unaffected (n¼66)
Sociodemographics
Age: mean (SD) 47.4 (9.8)* 39.4 (10.4)* 44.9 (6.2)* 37.6 (10.3)*
Currently married/partner (%) 83 86 83 86
College or higher (%) 25 24 35 24
Employed (%) 62 68 70 70
Have children (%) 89* 74* 83 68
Want (more) children (%) 4* 28* 0* 33*
Religiously affiliated (%) 71* 57* 63 62
Medical history
Personal medical history of bc/oc
No cancer (%) — 100 — 100
Breast cancer only (%) 90 — 100 —
Ovarian cancer only (%) 8 — 0 —
Breast and ovarian cancer (%) 2 — 0 —
Family medical history of bc/oc
Breast cancer only (%) 74* 27* 59* 12*
Ovarian cancer only (%) 2* 5* 0* 4*
Breast and ovarian cancer (%) 24* 68* 41* 84*
Time since last cancer diagnosis:
mean (SD)
4.7 (5.9) — 5.2 (5.9) —
Index case 95* 11* 78* 4*
Having first degree relatives with
bc/oc (%)
57 66 70 65
Having first degree relatives who died
of bc/oc (%)
24* 38* 35 33
bc, breast cancer; oc, ovarian cancer.
*Significant difference (P 0.05) between affected and unaffected women (independent t-test, w2-test).
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TABLE II. Mean Scores (SD) on the Outcome Variables and Independent t-Tests for Affected Versus Unaffected Women in the Total
Sample at Baseline
Affected Unaffected
t PN Mean (SD) N Mean (SD)
Well-being
Anxiety (STAI-state) 187 40.6 (11.0) 176 38.8 (11.2) 1.50 0.14
Depression (CESD) 191 10.0 (8.6) 176 7.6 (8.0) 2.81 0.01
Cancer related distress (IES) 187 20.7 (15.0) 176 17.4 (13.0) 2.20 0.03
General health 192 7.3 (1.6) 174 7.6 (1.5) 2.10 0.04
Decision making
Valuation of PM 167 5.6 (2.4) 173 4.4 (2.6) 4.48 <0.001
Valuation of BS 170 7.1 (2.4) 174 7.7 (2.3) 2.20 0.03
Valuation of PO 168 7.1 (2.2) 170 6.5 (2.7) 2.14 0.03
Valuation of OS 168 6.2 (2.7) 169 6.1 (3.0) 0.17 0.86
Strength of treatment preference 148 2.5 (1.1) 165 2.7 (1.1) 1.54 0.13
Decision uncertainty 167 2.9 (1.1) 173 2.6 (1.1) 1.85 0.07
Preference for decision making 158 3.5 (0.6) 172 3.8 (0.6) 3.57 <0.01
PM, prophylactic mastectomy; BS, breast cancer screening; PO, prophylactic oophorectomy; OS, ovarian cancer screening.
TABLE III. Mean Scores (SD) on the Outcome Variables (at Baseline and at Follow-Up) and Repeated Measures Analysis of Variance
for Affected Versus Unaffected Women in the Subsample of Mutation Carriers
N
Mean (SD) Test of overall trend
Baseline Follow-up Effect F P
Well-being
Anxiety (STAI-state) Affected 23 40.4 (11.5) 44.7 (11.1) Ca 1.98 0.16
Unaffected 64 38.5 (10.9) 39.3 (12.7) Time 5.24 0.03
Interact 2.48 0.12
Depression (CESD) Affected 23 8.7 (8.3) 12.7 (8.7) Ca 0.87 0.35




Affected 22 17.6 (13.1) 25.2 (12.3) Ca 0.50 0.48
Unaffected 64 17.9 (13.3) 20.5 (15.4) Time 12.55 <0.01
Interact 3.00 0.09
General health Affected 22 7.8 (1.3) 7.1 (1.5) Ca 0.77 0.38
Unaffected 60 8.0 (1.6) 7.6 (1.9) Time 6.77 0.01
Interact 0.70 0.41
Decision making
Valuation of PM Affected 21 5.3 (2.4) 6.7 (2.3)* Ca 6.13 0.02
Unaffected 64 4.3 (2.7) 4.8 (2.6)* Time 13.18 <0.001
Interact 2.72 0.10
Valuation of BS Affected 21 7.0 (1.8) 6.0 (2.2) Ca 5.02 0.03
Unaffected 64 8.0 (2.1) 7.0 (2.3) Time 15.82 <0.001
Interact 0.00 0.98
Valuation of PO Affected 20 6.8 (2.3) 7.6 (2.3) Ca 1.86 0.18
Unaffected 60 6.0 (2.9) 6.7 (2.7) Time 7.58 0.01
Interact 0.10 0.75
Valuation of OS Affected 20 5.7 (2.6) 4.7 (2.5) Ca 2.13 0.15
Unaffected 60 6.7 (2.9) 5.7 (2.9) Time 12.05 <0.01
Interact 0.00 0.98
Decision making
Strength of treatment pref. Affected 19 24 (1.1) 3.3 (0.6) Ca 0.00 0.98
Unaffected 58 2.8 (1.1) 2.9 (0.9) Time 9.80 <0.01
Interact 7.89 0.01
Decision uncertainty Affected 21 2.8 (1.1) 2.2 (1.0) Ca 0.42 0.52
Unaffected 61 2.6 (1.1) 2.2 (1.0) Time 12.38 <0.01
Interact 0.37 0.55
Preference for DM Affected 20 3.5 (0.6) 3.7 (0.8) Ca 1.12 0.29
Unaffected 61 3.7 (0.6) 3.8 (0.7) Time 1.51 0.22
Interact 0.49 0.49
Ca, cancer history; Interact, interaction between cancer history and time; PM, prophylactic mastectomy; BS, breast cancer screening; PO, prophylactic
oophorectomy; OS, ovarian cancer screening; DM, decision making.
*Significant difference (P 0.05) between affected and unaffected women at follow-up (independent t-test).
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effect of cancer history (affected versus unaffected), a
main effect of time (impact of a positive test result), and
no interaction of cancer history and time was found for
all outcomes. So both affected and unaffected women
reported an increase in anxiety, depression, and cancer
related distress, and a decrease in general health over
time. Although the interactions of cancer history and
time were not significant, the positive test result tended
to have a greater impact on anxiety and cancer related
distress in affected women.
Well-being and time since diagnosis. Table IV
presents themeanscores onwell-beingand the results of
the independent t-tests for affected women diagnosed
with cancer 1 year previously versus those diagnosed
>1 year at baseline. Affected women diagnosed 1 year
scored higher on anxiety, depression, and cancer related
distress. In fact, affected women diagnosed>1 year and
unaffectedwomen had similar baseline scores, as can be
seen by comparing Table II column 5 with Table IV
column 5.
Thefifth columnofTableVpresent themeanscores on
well-being for affectedwomendiagnosed1year and>1
year in the subsample of mutation carriers at follow-up;
the results of the independent t-tests are not presented.
Affected women diagnosed 1 year scored higher on
anxiety (t¼ 2.06, P¼0.05) and cancer related distress
(t¼ 2.11,P¼ 0.05). Again, affectedwomendiagnosed>1
year and unaffected women had similar follow-up
scores, as can be seen by comparing Table III column 5
with Table V column 5.
The last three columns of Table V present the results
of the repeated measures analysis of variance; no
interaction of time since diagnosis (1 year versus
>1 year) and time (impact of a positive test result) was
found for any of the outcomes.
Treatment choice. At baseline, within the total
sample, more affected than unaffected women intended
to obtain prophylactic mastectomy (w2¼ 8.86; P<0.01);
no difference was found for the treatment choice related
to the ovaries (w2¼ 0.42; P¼ 0.52). At follow-up, within
the subsample of mutation carriers, more affected than
unaffected women intended to obtain prophylactic
oophorectomy (w2¼ 3.96; P¼0.05); no difference was
found for the treatment choice related to the breasts
(w2¼ 1.58; P¼0.21).
Table VI presents the intended treatment choice
related to the breasts and ovaries for affected and
unaffected mutation carriers, at baseline and at follow-
up. At follow-up, all affected women had made a
treatment choice, while some unaffected women were
still undecided. From baseline to follow-up, most muta-
tion carriers did not change their intended treatment
choice.
Decision making. Table II presents the mean
scores on the decision making outcomes and the results
of the independent t-tests for affected versus unaffected
women in the total sample at baseline. Affected women
had higher valuations for prophylactic mastectomy and
oophorectomy, and a lower valuation for breast cancer
screening. Furthermore, affected women had a lower
preference for decision making, and tended to report a
higher decision uncertainty.
The fifth column of Table III presents themean scores
on the decision making outcomes for affected and
unaffectedwomen in the subsample ofmutation carriers
at follow-up; the results of the independent t-tests are
not presented. Affected women had a higher valuation
for prophylactic mastectomy (t¼ 2.98; P0.01). No
differences were found for the other decision making
outcomes.
The last three columns of Table III present the results
of the repeated measures analysis of variance. A main
effect of cancer history (affected versus unaffected) was
found for the valuation of prophylactic mastectomy and
breast cancer screening; affected women had a higher
valuation for prophylactic mastectomy and a lower
valuation for breast cancer screening. Also, a main
effect of time (impact of a positive test result) was found
for all decision making outcomes except the preference
for decision making; both affected and unaffected
women reported a higher valuation for prophylactic
surgery, a lower valuation for screening, an increase in
strength of treatment preference, and a decrease in
decision uncertainty over time. Finally, an interactive
effect of cancer history and time was found for strength
of treatment preference; strength of treatment prefer-
ence increased stronger over time for affected women.
DISCUSSION
Summary of Results
This study is the first to show that general (STAI-
state, CES-D) and cancer related distress (IES) increase
when assessed 2 weeks after disclosure of a positive
BRCA1 orBRCA2 test result in a relatively large sample
of mutation carriers. The sample size enabled us to
TABLE IV. Mean Scores (SD) on Well-Being and Independent t-Tests for Affected Women Diagnosed 1 Year Versus >1 Year
at Baseline
Diagnosed 1 year Diagnosed >1 year
t PN Mean (SD) N Mean (SD)
Well-being at baseline
Anxiety (STAI-state) 91 42.4 (10.9) 93 38.9 (11.0) 2.14 0.03
Depression (CESD) 92 11.4 (8.3) 96 8.7 (8.6) 2.20 0.03
Cancer related distress
(IES)
91 23.2 (15.2) 93 18.8 (14.5) 1.99 0.05
General health 92 7.1 (1.6) 97 7.4 (1.6) 1.18 0.24
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assess the differential impact on affected opposed to
unaffected women.We found that both groups showed a
similar increase on these outcomes, with a hint towards
a more profound impact on affected women. We also
found that affected women diagnosed 1 year pre-
viously reported an elevated general and cancer specific
distress compared to women diagnosed >1 year both at
baseline and at follow-up. With respect to treatment
choice, more affected women intended to obtain prophy-
lactic surgery and valued it higher at both time points.
With respect to the other decision making outcomes,
affected women had a lower preference for decision
making at baseline; no differences were found at follow-
up. At follow-up, both affected and unaffected women
showed an increase in strength of treatment preference
and a decrease in decision uncertainty.
Well-Being
Previous studies evaluating the impact of genetic
testing and a positive test result, showed low levels of
general and cancer related distress [Lerman et al., 1996;
Croyle et al., 1997;Lodder et al., 1999, 2001;Coyne et al.,
2000; Wood et al., 2000; Schwartz et al., 2002]. Also in
our study, mean levels of anxiety, depression, and
cancer related distress were below clinically significant
levels. Women who had received a positive test result
reported a significant increase in anxiety, depression,
and cancer related distress. Although this seems logical,
most previous studies showed no increased distress in
mutation carriers [Lerman et al., 1996; Croyle et al.,
1997; Lodder et al., 2001; Schwartz et al., 2002]. Only
one study [Wood et al., 2000] found a non significant
TABLE V. Mean Scores (SD) on Well-Being (at Baseline and at Follow-Up) and Repeated Measures Analysis of Variance for Affected
Women Diagnosed 1 Year Versus >1 Year in the Subsample of Mutation Carriers
Mean (SD) Test of overall trend
N Baseline Follow-up Effect F P
Well-being
Anxiety (STAI-state) 1 year 11 45.5 (12.5) 49.4 (11.2)* t.s.d. 6.02 0.02
>1 year 12 35.8 (8.7) 40.5 (9.5)* Time 3.65 0.07
Interact 0.03 0.87
Depression (CESD) 1 year 11 11.9 (8.3) 15.0 (7.7) t.s.d. 2.81 0.11




1 year 11 22.5 (12.4) 30.4 (11.7)* t.s.d. 5.53 0.03
>1 year 11 12.7 (12.5) 20.1 (11.2)* Time 7.78 0.01
Interact 0.01 0.92
General health 1 year 11 7.4 (1.4) 6.8 (1.7) t.s.d. 3.29 0.09
>1 year 11 8.3 (0.9) 7.5 (1.1) Time 3.28 0.09
Interact 0.13 0.72
t.s.d., time since diagnosis; Interact, interaction between time since diagnosis and time.
*Significant difference (P 0.05) between affected women diagnosed 1 year and >1 year at follow-up (independent t-test).
TABLE VI. Treatment Intentions at Baseline and at Follow-Up for Affected and Unaffected
Mutation Carriers
PM BS ? Total
Follow-up intentions breasts
Affected Baseline intentions breasts PM 7 2 — 9
BS 1 9 — 10
? 1 1 — 2
Total 9 12 — 21
Unaffected PM 12 3 1 16
BS 4 37 1 42
? 2 3 1 6
Total 18 43 3 64
Follow-up intentions ovaries
PO OS ?
Affected Baseline intentions ovaries PO 12 — — 12
OS 1 2 — 3
? 5 1 — 6
Total 18 3 — 21
Unaffected PO 28 6 1 35
OS 8 11 2 21
? 2 1 2 5
Total 38 18 5 61
PM, prophylactic mastectomy; BS, breast cancer screening; PO, prophylactic oophorectomy; OS, ovarian cancer
screening; ?, undecided.
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trend towards an increase in distress. This study inclu-
ded a small sample size of affected mutation carriers
(n¼10). Earlier studies [Lerman et al., 1996; Croyle
et al., 1997], with 53 and 25 mutation carriers respecti-
vely, did not show an increase in distress. However,
they included both men and women who were aware
that a BRCA1/2 mutation was segregating in their
family, and who had been participating in genetic
studies for a long time. This highly selected sample
may not be representative for a clinic-based population.
However, two other clinic-based studies also did not find
an increase in distress [Lodder et al., 2001; Schwartz
et al., 2002]. One study [Lodder et al., 2001] included a
small sample of unaffected mutation carriers only
(n¼25). The other study [Schwartz et al., 2002] included
a larger sample of both affected index cases (n¼ 43) and
their unaffected relatives (n¼ 35), but their follow-up
assessment was 6 months after disclosure of the test
result whereas ours was after 2 weeks. Therefore, it is
conceivable that either a small sample size or a long
interval between test result and assessment, have
masked the short-term negative effects on general and
cancer related distress in mutation carriers in previous
studies. The point in time at which our follow-up
questionnaire was filled out may have contributed to
our finding of an increase in distress; it is unlikely that
psychological reactions are fully balanced and that
adaptation is complete so shortly after learning their
carrier status. Possibly, a positive test result causes
transient distress on the short term only.
Differential Well-Being in Affected Versus
Unaffected Women
Affected women scored higher on depression and
cancer related distress and lower on general health at
baseline, and tended to score higher onanxiety at follow-
up. We assume that having a cancer history and
especially a short time since cancer diagnosis explained
the increased distress in affected women. Indeed, we
found that affected women diagnosed 1 year pre-
viously had higher distress levels as those diagnosed
>1 year, who scored almost identical as unaffected
women. This was also found in a previous study [Wood
et al., 2000].
Other confounding variables, such as being an index
case (meaning that usually more time is needed for
DNA-analysis and facing the task of informing their
family after a positive test result) or older age, are also
candidates for explaining the worse well-being of affec-
tedwomen at baseline. However, they could be ruled out
as explanation because in a previous study [Randall
et al., 2001] was found that levels of distress in affected
women did not depend on whether or not genetic testing
was initiated. We checked whether older age was
associated with an increased distress level, but this
was not the case (data not shown).
Furthermore, affected women tended to experience a
stronger increase in anxiety and cancer related distress
after a positive test result when compared to unaffected
women; within the group of affected women, this
was independent of time since diagnosis. We can only
speculate about the cause of this greater emotional
reactivity. A plausible explanation might be that affec-
ted women are additionally distressed as a consequence
of a reactivation of negative feelings related to their
previous cancer diagnosis and treatment; they do not
only have to copewith their carrier status, but also to re-
evaluate their disease in the light of this new informa-
tion. Other explanations are suggested by previous
studies; one indicated that affected index cases experi-
enced difficulties in transmitting their results to
families [Bonadona et al., 2002], and another suggested
that affected women reported more distress after a
positive test result because they had underestimated its
impact [Dorval et al., 2000].
Associations Between Decision Uncertainty
and Well-Being
Well-being is expected to be worse in women who feel
more uncertain about which treatment to choose.
Indeed, after disclosure of a positive test result, we
found that a worse well-being was associated with a
higher decision uncertainty; the correlations of decision
uncertainty with anxiety, depression, cancer related
distress, and general health were 0.34 (P¼ 0.00), 0.28
(P¼0.01), 0.39 (P¼0.00), and 0.30 (P¼0.01), respec-
tively. At baseline, however, when the treatment choice
is still hypothetical, no such association were found
(data not shown). These findings underline the impact
of the decision making process on well-being after a
positive test result.
Surprisingly, we found that over time, a worse well-
being was concomitant with a lower decision uncer-
tainty (see Table III). Several explanations could be
given. Possibly, womenmay bemore certain about their
treatment choice, simply because they are certain about
their carriers status. Another explanation is that
mutation carriers who feel more certain about their
choice, also have a stronger feeling that they have no
choice and therefore experience a loss in well-being.
Furthermore, women might bolster their decision to
cope with the distress caused by a positive test result; in
other words, fear and distress may induce a wish to act
firmly.
Limitations
Several limitations should be considered. First, the
sample of mutation carriers is relatively small. Never-
theless, it is the greatest consecutive clinic-based
sample of mutation carriers to date to study differences
between affected and unaffected women. Because we
included a consecutive sample, heterogeneity exists in
our sample. Not all affected women were an index case,
someweremembers of a family inwhich amutationwas
found before. And not all unaffected womenwere part of
a family with a knownmutation, some were index cases
themselves. Second, all of our mutation carriers had
received an informative decision aid. Thus, it could be
argued that changes in well-being, treatment choice,
and decision making outcomes were a result of the
informative decision aid and not of disclosure of a
positive test result. However, the informative decision
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aid did not affect well-being, strength of treatment
preference, decision uncertainty, and preference for
decisionmaking, although it did lead tomore considera-
tions towards prophylactic surgery and higher valua-
tions for prophylactic surgery and lower valuations for
screening [Van Roosmalen et al., 2002b]. Therefore, it is
reasonable to attribute the impact of a positive test
result on well-being, strength of treatment preference,
and decision uncertainty, to disclosure of a positive test
result and not to the informative decision aid. Third,
long term follow-up was not obtained because in
the second part of our study, mutation carriers will be
randomized to a second decision aid, consisting of value
assessment and individualized treatment information
derived from a decision model [Van Roosmalen et al.,
2002a], or to the control group. The follow-up time point
reported here, will be the baseline assessment for this
second intervention.
Clinical Recommendations
In the Netherlands, protocols for psychosocial care in
genetic counseling for a possible BRCA1/2mutation are
often based on previous experience from predictive
testing for Huntington disease [Bleiker et al., 2001]. A
very important difference with a hereditary breast/
ovarian cancer syndrome is that it is not possible to
prevent Huntington disease or to detect it in an early
curable stage. Furthermore, there exists no sporadic
form of the disease; people affected by Huntington
disease always carry themutation. Finally, Huntington
disease is always fatal. Consequently, there is no group
of affected mutation carriers for whom DNA-diagnosis
implicates a substantial change in prognosis or prob-
ability to develop a new serious disease. In contrast to
this situation, the large majority of breast cancers is
sporadic and relatives of sporadic breast cancer patients
usually only face a minor increase in breast cancer risk.
Diagnosing a BRCA1/2 mutation in a breast cancer
patient implicates a large probability of developing a
second primary breast cancer and/or ovarian cancer.
Until now, protocols for psychosocial care in genetic
counseling for a possible BRCA1/2 mutation have been
mainly tailored towards unaffected women, analogous
to the protocol for Huntington disease [Bleiker et al.,
2001].Our results indicate that thismaynot be justified.
Affected women, especially those who have been recen-
tly diagnosed with cancer, may need more support than
unaffectedwomen.We suggest to follow this groupmore
closely and to stimulate contact with a psychosocial
worker for support. Our research does not permit us to
give specific recommendations about the form of these
interventions but this should be the topic of further
research.
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